NILEMDO® / NUSTENDI®: Prodrug that inhibits adenosine triphosphate citrate lyase by reducing intracellular cholesterol, increasing the number of LDL receptors on the cell surface, decreasing plasma LDL cholesterol (LDL-c) concentration.

NILEMDO® / NUSTENDI®: Profármaco que inhibe la adenosina trifosfato citrato liasa reduciendo el colesterol intracelular, lo que aumenta el número de receptores de LDL en la superficie celular, disminuyendo la concentración plasmática de C-LDL.

JARDIANCE®: Treatment of symptomatic, chronic heart failure (HF) with reduced (HFrEF, EF≤40%), mildly-reduced (HFmrEF, EF 41-49%) and preserved (HFpEF, EF>50%) ejection fraction. In Spain, it is funded for HFrEF patients with increased NT-proBNP levels and not controlled with recommended first-line therapies (ACE inhibitors or ARBs or sacubitril/valsartan with beta-blocker and mineralocorticoid receptor antagonist; unless intolerance or contraindication), as well as in symptomatic HFpEF with increased NT-proBNP levels. It is also labeled for the treatment of type 2 diabetes mellitus.

VERQUVO®: Additional therapy for adults with HF and EF <40% who are stabilised and euvolemic after a recent decompensation event requiring IV diuretics and received best medical care (a betablocker, an ACE-I or ARB or sacubitril/valsartan and a sodium-glucose cotransporter 2 inhibitor).